One development history
In 1993, the Americans invented the argon-helium cryotherapy system, commonly known as argon-helium knife, using dozens of space patent technologies.
In 1998, after 5 years of clinical trials, the FDA approved the argon-helium knife into clinical application. At the same time, the US argon-helium knife also obtained the European Union's CE certification and began to be used for targeted therapy of solid tumors.
In 1999, Professor Zhang Jiren from Zhujiang Hospital of Guangzhou First Military Medical University introduced the first argon-helium knife in Asia and established the first argon-helium knife training and demonstration center in Asia, laying a foundation for the promotion of argon-helium knife technology in China basis.
In 2000, the Japanese (Tokyo University, Japan) learned the argon-helium knife tumor treatment technology from China and began clinical application. Two years later, the University of Tokyo published a paper that confirmed that the American argon-helium knife targeted therapy for liver cancer is more than 97% effective.
In 2000, the U.S. Treasury Department included the treatment of prostate cancer with argon helium knife into the universal health insurance plan.
In 2002, the American Urological Association announced that the first choice for the treatment of prostate cancer was argon-helium knife, and the effective rate of argon-helium knife treatment reached more than 97%, thus rewriting the history of surgical treatment of prostate cancer in the United States.
In 2003, there were more than 300 hospitals using argon-helium knife in the United States, and more than 160 in Europe, and 30 hospitals in China have begun to use argon-helium knife technology.
In 2003, Professor Zhang Jiren from China summarized and edited the world's first argon-helium knife technical standard document "Ar-Helium Targeted Tumor Therapy Technology".
In 2003, the International Conference on Targeted Cancer Therapy recognized that argon-helium knife therapy is one of the best treatments for lung cancer. In the United States, it has become a routine equipment for specialized treatment of lung cancer.
In 2004, the Tumor Center of Qianfoshan Hospital of Shandong Province introduced the argon-helium knife targeted therapy system to fully carry out targeted therapy of tumors.
In 2008, the International Cryotherapy Association Tumor Treatment Symposium was held in Qianfoshan Hospital of Shandong Province.
——Malignant solid tumors:
Liver cancer, lung cancer, brain tumor, breast cancer, pancreatic cancer, thyroid cancer, prostate cancer, kidney and adrenal tumors, abdominal and pelvic tumors, bone tumors, soft tissue tumors, head and neck and skin tumors, metastatic gastrointestinal tumors and other solid tumors
——Benign tumors and benign hyperplastic lesions:
Prostatic hyperplasia, benign breast tumors, hemangioma, uterine fibroids, cysts, warts, hemorrhoids, recurrent precancerous lesions, oral leukoplakia, etc.
Peripheral lung cancer that cannot tolerate surgical resection
Surgical exploration of unresectable primary lung cancer
Central lung cancer involving the bronchi
Part of central lung cancer near the hilar area
More limited metastatic lung cancer
Primary massive liver cancer with a diameter of 10 cm or the tumor occupies less than 50% of the liver volume
There are less than 3 primary liver cancer cancer foci, and less than 5 metastatic foci
Those whose liver function evaluation is Child A or B
Patients with localized extrahepatic metastases that can be surgically or combined with cryosurgery
Bilateral or multiple small kidney tumors
A single tumor in the renal parenchyma is less than 3 cm
The basic renal function is poor and cannot be operated. The tumor invasion range is less than 1/3
Partial nephrectomy is still the best treatment for unilateral renal tumors with compensatory renal function
Patients with one-lobe or two-lobe prostate cancer
Those who are older and cannot bear other operations
Those who have undergone castration or androgen reduction therapy or relapse or remain after tumor surgery
Those who have failed radiotherapy or chemotherapy but have no other treatment options
For some bone metastases but the whole body is in good condition, local cryosurgery can still be used for treatment
Benign prostatic hyperplasia
Have clinical manifestations of prostate hyperplasia
No urethral stricture
No serious heart or lung disease
No obvious bacterial prostatitis
No obvious abnormal liver and kidney function
Normal blood clotting mechanism
Glioma: especially tumors whose boundaries cannot be distinguished during surgery
Meningiomas: (accounting for 10% of brain tumors) especially in the deep brain and skull base vascular areas
Other brain tumors: cavernous hemangioma, giant pituitary tumor, chordoma, etc.
Surgery combined with argon-helium targeted therapy for advanced pancreatic cancer
Patients with advanced pancreatic cancer who cannot undergo conventional surgical resection and cannot tolerate surgical resection have limited lesions and have not yet developed distant metastasis.
Surgery combined with argon-helium targeted therapy for advanced gallbladder cancer
In patients with stage Ⅴ, the liver has limited solitary infiltrating mass, or a small amount of scattered metastases, without invasion
And most of the liver parenchyma
After the original lesion is removed, there are still other scattered metastatic lesions in the liver that cannot be removed
Patients with stage Ⅲ and Ⅳ undergo expanded cholecystectomy or wedge resection of the liver, the liver wound
Those with residual cancer
After radical surgery for gallbladder cancer, local liver recurrence and metastasis
Old age, serious comorbidities, major organ dysfunction, and intolerance of severe surgical resection
Percutaneous Argon Helium Targeted Treatment of Pelvic Tumors
Mid- to late-stage patients who have lost opportunities for conventional radical surgery
Localized pelvic metastasis, low mass, and no invasion of the intestinal cavity
Primary tumor of the sacrum or recurrence after surgery
Intraoperative argon-helium targeted therapy for pelvic tumors under direct vision-indications
Uterine and cervical cancer recurrence after surgery
Recurrence of rectal cancer after surgery and those who have difficulty in percutaneous puncture and freezing
Patients with pelvic metastatic cancer that cannot be surgically removed
Although the tumor has infiltrated the rectum, the residual tumor can still be frozen inactivated after the replacement of artificial anus
Intraoperative argon-helium targeted therapy for pelvic tumors under direct vision-contraindications
Tumor infiltrates bilateral ureters and bladder triangle
Those whose tumor has spread widely
Those who are in poor general condition and cannot tolerate surgery
Three treatment advantages
① The patient has little injury-no surgery, no bleeding or less bleeding, percutaneous or translaparoscopic treatment, the patient is less painful;
② The effect is remarkable! —For tumors with large lesions, argon-helium cryosurgery can kill 80% of cancer cells, and for relatively small tumor lesions, cancer cells can be eliminated 100%-with a good success rate;
③ The operation is easy, the success rate is high, and the complications are few; and because of freezing hemostasis and pain relief, patients are easy to accept;
④ The damage is slight, non-toxic to normal organs, tissues and cells, and can be repeated and repeated;
⑤ The operation time is short, the trauma is small, the patient recovers quickly, the requirements for the patient are relatively low, and the average patient can tolerate it;
⑥ It can be administered alone or combined with radiotherapy, chemotherapy or surgery;
⑦ The cost is low, and the operation cost is about 15,000. Generally, one treatment can be completed, and it can be discharged after 3-5 days of observation;
⑧ The tumor immunity caused by argon-helium freezing is significantly improved, and the cryotherapy is equivalent to producing tumor vaccine in the body;
⑨ It is suitable for patients with solid tumors of various stages, especially for cases that cannot be operated or other treatments have failed.